Galectin Therapeutics (GALT) Cash from Investing Activities (2011 - 2014)

Galectin Therapeutics' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$400000.0 for Q1 2014.

• In Q1 2014, Cash from Investing Activities changed N/A year-over-year to -$400000.0; the TTM figure through Dec 2014 stood at -$400000.0 (changed N/A YoY), while the FY2014 annual figure was -$400000.0, changed N/A from the prior year.
• Cash from Investing Activities for Q1 2014 stood at -$400000.0, down from $56000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $56000.0 in Q4 2012, with the low at -$400000.0 in Q1 2014.
• The 3-year median for Cash from Investing Activities is -$5000.0 (2011), against an average of -$88500.0.
• Peak annual rise in Cash from Investing Activities reached 1220.0% in 2012, while the deepest fall reached 1220.0% in 2012.
• Galectin Therapeutics' Cash from Investing Activities stood at -$5000.0 in 2011, then surged by 1220.0% to $56000.0 in 2012, then plunged by 814.29% to -$400000.0 in 2014.
• Business Quant data shows GALT's Cash from Investing Activities at -$400000.0 in Q1 2014, $56000.0 in Q4 2012, and -$5000.0 in Q4 2011.